{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T06:04:32Z","timestamp":1789452272434,"version":"build-2803163510"},"reference-count":26,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T00:00:00Z","timestamp":1789430400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>The introduction of The Cancer Genome Atlas (TCGA) had made a paradigm shift towards molecular based classification that impacted the treatment of endometrial cancer (EC). Here we aim to share our initial experience with the implementation of molecular testing into daily clinical practice of endometrial cancer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This is an ambispective cohort study on prospectively collected data of 350 endometrial cancer patients who underwent primary surgery between 2020 and 2024 at our institution. Clinical, radiological, pathological and treatment related data were obtained through hospital management systems (HMS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The median age of our cohort was 59 years. Most of the patients had endometrioid histology (267, 76.3%) and early-stage disease (288, 82.3%). Effectively 64 patients had p53 mutation if 8 double classifiers with p53 abnormality were excluded.115 patients had mismatch repair deficient (MMRd) tumors. Out of 350 patients POLE mutation was tested in 110 (31.4%). 5 patients out of these 110 (4.5%) had pathogenic POLE mutations and one had POLE variant of unknown significance (VUS). None of the patients with POLE ultra-mutated tumors received any adjuvant treatment or developed any recurrences. All of 11\/64 p53 mutant patients (17.2%) developed systemic metastatic recurrences. At a median follow-up of 33 months, 3-year overall survival (OS) of POLE ultra-mutated and p53abn subgroups were 100% and 87% respectively. MMRd and nonspecific molecular pattern (NSMP) subgroups achieved OS of 97% and 96% respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Assessment of the molecular profile is currently a standard investigation for evaluation of EC at our institution. This study represents a real-world experience of routine molecular marker testing among patients with EC from a tertiary care center of India.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Synopsis<\/jats:title>\n                    <jats:p>We aim to share our initial experience with the implementation of molecular testing into daily clinical practice of endometrial cancer. Phase wise implementation of molecular testing started at our institute in 2015.It became routine in 2023. POLE ultra-mutated tumors have shown excellent prognosis. None of those patients developed any recurrences even without any adjuvant treatment. p53 abnormal tumors have the worst prognosis, with systemic recurrence being the predominant pattern of failure. MMRd and NSMP subset of patients performed moderately in between POLE mutant and p53 abnormal tumors.<\/jats:p>\n                    <jats:p>Molecular profiling is the most important futuristic step towards optimized adjuvant treatment for endometrial cancer in a developing country like India.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1923324","type":"journal-article","created":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T05:35:48Z","timestamp":1789450548000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Impact of molecular profiling in patients with endometrial cancer: real world experience from India"],"prefix":"10.3389","volume":"16","author":[{"given":"Richa","family":"Kaushik","sequence":"first","affiliation":[{"name":"Department of Gynecological Oncosurgery, Tata Medical Centre","place":["Kolkata, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Basumita","family":"Chakraborti","sequence":"additional","affiliation":[{"name":"Department of Gynecological Oncosurgery, Tata Medical Centre","place":["Kolkata, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anik","family":"Ghosh","sequence":"additional","affiliation":[{"name":"Department of Gynecological Oncosurgery, Tata Medical Centre","place":["Kolkata, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santam","family":"Chakraborty","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Tata Medical Centre","place":["Kolkata, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tapesh","family":"Bhattacharyya","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Tata Medical Centre","place":["Kolkata, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jagannath","family":"Mishra","sequence":"additional","affiliation":[{"name":"Department of Gynecological Oncosurgery, Tata Medical Centre","place":["Kolkata, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subhashree","family":"Rout","sequence":"additional","affiliation":[{"name":"Department of Gynecological Oncosurgery, Tata Medical Centre","place":["Kolkata, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Divya","family":"Midha","sequence":"additional","affiliation":[{"name":"Department of Pathology, Tata Medical Centre","place":["Kolkata, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepak","family":"Mishra","sequence":"additional","affiliation":[{"name":"Department of Molecular Pathology, Tata Medical Centre","place":["Kolkata, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sushant","family":"Vinarkar","sequence":"additional","affiliation":[{"name":"Department of Molecular Pathology, Tata Medical Centre","place":["Kolkata, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Somnath","family":"Roy","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Tata Medical Centre","place":["Kolkata, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oindrila Roy","family":"Chowdhury","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Tata Medical Centre","place":["Kolkata, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaydip","family":"Bhaumik","sequence":"additional","affiliation":[{"name":"Department of Gynecological Oncosurgery, Tata Medical Centre","place":["Kolkata, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/0090-8258(83)90111-7","article-title":"Two pathogenetic types of endometrial carcinoma","volume":"15","author":"Bokhman","year":"1983","journal-title":"Gynecol Oncol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2005.11.032","article-title":"Pelvic lymph node count is an important prognostic variable for FIGO stage I and II endometrial carcinoma with high-risk histology","volume":"102","author":"Lutman","year":"2006","journal-title":"Gynecol Oncol"},{"key":"B3","first-page":"67","article-title":"Integrated genomic characterization of endometrial carcinoma","volume":"49","author":"Kandoth","year":"2013","journal-title":"Nature"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2015.190","article-title":"A clinically applicable molecular-based classification for endometrial cancers","volume":"113","author":"Talhouk","year":"2015","journal-title":"Br J Cancer"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-15-2878","article-title":"Improved risk assessment by integrating molecular and clinicopathological factors in early-stage endometrial cancer combined analysis of the PORTEC cohorts","volume":"22","author":"Stelloo","year":"2016","journal-title":"Clin Cancer Res"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.30496","article-title":"Confirmation of ProMisE: A simple, genomics-based clinical classifier for endometrial cancer","volume":"123","author":"Talhouk","year":"2017","journal-title":"Cancer"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy058","article-title":"Final validation of the ProMisE molecular classifier for endometrial carcinoma in a large population-based case series","volume":"29","author":"Kommoss","year":"2018","journal-title":"Ann Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1200\/jco.20.00549","article-title":"Molecular classification of the PORTEC-3 trial for high-risk endometrial cancer: Impact on prognosis and benefit from adjuvant therapy","volume":"38","author":"Castillo","year":"2020","journal-title":"J Clin Oncol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.radonc.2020.11.018","article-title":"ESGO\/ESTRO\/ESP guidelines for the management of patients with endometrial carcinoma","volume":"31","author":"Concin","year":"2021","journal-title":"Int J Gynecol Cancer"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.00831","article-title":"Detection of POLE subtypes in high-grade endometrioid carcinoma by BaseScope-ISH assay","volume":"9","author":"Yu","year":"2019","journal-title":"Front Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1002\/ijgo.15277","article-title":"FIGO staging of endometrial cancer","volume":"162","author":"Berek","year":"2023","journal-title":"Int J Gynecol Obstet"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1200\/po-24-00815","article-title":"Real world molecular testing rates and patterns in patients with primary advanced or recurrent endometrial cancer in the United States","volume":"28","author":"Chen","year":"2025","journal-title":"JCO Precis Oncol"},{"key":"B13","article-title":"Evaluation of treatment effects in patients with endometrial cancer and POLE mutations: An individual patient data meta-analysis","volume":"127","author":"Mc Alpine","year":"2021","journal-title":"Cancer"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1200\/jco.23.00062","article-title":"Molecular classification predicts response to radiotherapy in the randomized PORTEC-1 and PORTEC-2 trials for early-stage endometrioid endometrial cancer","volume":"41","author":"Horeweg","year":"2023","journal-title":"J Clin Oncol"},{"key":"B15","article-title":"Refining adjuvant treatment in endometrial cancer based on molecular features: the RAINBO clinical trial program","volume":"33","year":"2022","journal-title":"Int J Gynecol Cancer"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1136\/ijgc-2020-001929","article-title":"PORTEC-4a: international randomized trial of molecular profile-based adjuvant treatment for women with high-intermediate risk endometrial cancer","volume":"30","author":"van den Heerik","year":"2020","journal-title":"Int J Gynecol Cancer"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(25)00167-6","article-title":"ESGO\u2013ESTRO\u2013ESP guidelines for the management of patients with endometrial carcinoma: update 2025","volume":"26","author":"Concin","year":"2025","journal-title":"Lancet Oncol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/go.22.00384","article-title":"QPOLE: A quick, simple, and cheap alternative for POLE sequencing in endometrial cancer by multiplex genotyping quantitative polymerase chain reaction","volume":"9","author":"Van den Heerik","year":"2023","journal-title":"J Global Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/s2589-7500(22)00210-2","article-title":"Interpretable deep learning model to predict the molecular classification of endometrial cancer from haematoxylin and eosin-stained whole-slide images: a combined analysis of the PORTEC randomised trials and clinical cohorts","volume":"5","author":"Fremond","year":"2023","journal-title":"Lancet Digital Health"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2022.02.024","article-title":"Time to first recurrence, pattern of recurrence, and survival after recurrence in endometrial cancer according to the molecular classification","volume":"165","author":"Siegenthaler","year":"2022","journal-title":"Gynecol Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2020.05.381","article-title":"Understanding the clinical implication of mismatch repair deficiency in endometrioid endometrial cancer through a prospective study","volume":"161","author":"Kim","year":"2021","journal-title":"Gynecol Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2008.20.2424","article-title":"Quality of life after pelvic radiotherapy or vaginal brachytherapy for endometrial cancer: First results of the randomized PORTEC-2 trial","volume":"27","author":"Nout","year":"2009","journal-title":"J Clin Oncol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2010.32.4590","article-title":"Long-term outcome and quality of life of patients with endometrial carcinoma treated with or without pelvic radiotherapy in the post operative radiation therapy in endometrial carcinoma 1 (PORTEC-1) trial","volume":"29","author":"Nout","year":"2011","journal-title":"J Clin Oncol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1136\/ijgc-2023-004534","article-title":"Endometrial adenocarcinoma recurring in the lung: impact of molecular profile and role of local therapies on prognosis","volume":"33","author":"Luzarraga Aznar","year":"2023","journal-title":"Int J Gynecol Cancer"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-018-0187-6","article-title":"L1CAM further stratified endometrial carcinoma patients with no specific molecular risk profile","volume":"119","author":"Kommoss","year":"2018","journal-title":"Br J Cancer"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-023-02141-0","article-title":"Prognostic refinement of NSMP high-risk endometrial cancers using oestrogen receptor immunohistochemistry","volume":"128","author":"Vermij","year":"2023","journal-title":"Br J Cancer"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1923324\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T05:35:50Z","timestamp":1789450550000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1923324\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,15]]},"references-count":26,"alternative-id":["10.3389\/fonc.2026.1923324"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1923324","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,15]]},"article-number":"1923324"}}